ATE450525T1 - Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten - Google Patents
Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonistenInfo
- Publication number
- ATE450525T1 ATE450525T1 AT06785168T AT06785168T ATE450525T1 AT E450525 T1 ATE450525 T1 AT E450525T1 AT 06785168 T AT06785168 T AT 06785168T AT 06785168 T AT06785168 T AT 06785168T AT E450525 T1 ATE450525 T1 AT E450525T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- sub
- optionally substituted
- histamine
- antagonists
- Prior art date
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000008369 airway response Effects 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 208000027744 congestion Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69217505P | 2005-06-20 | 2005-06-20 | |
| PCT/US2006/023937 WO2007002057A1 (en) | 2005-06-20 | 2006-06-19 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450525T1 true ATE450525T1 (de) | 2009-12-15 |
Family
ID=36968202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06785168T ATE450525T1 (de) | 2005-06-20 | 2006-06-19 | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7408066B2 (de) |
| EP (1) | EP1896453B1 (de) |
| JP (1) | JP2008543940A (de) |
| CN (1) | CN101203510A (de) |
| AT (1) | ATE450525T1 (de) |
| CA (1) | CA2609957A1 (de) |
| DE (1) | DE602006010864D1 (de) |
| ES (1) | ES2337728T3 (de) |
| MX (1) | MX2007016523A (de) |
| WO (1) | WO2007002057A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521445A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ |
| WO2010016554A1 (ja) * | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 環状アミン化合物 |
| CN102428069B (zh) | 2009-04-02 | 2014-04-02 | 盐野义制药株式会社 | 丙烯酰胺化合物及其用途 |
| EP2575815A4 (de) | 2010-06-04 | 2013-12-25 | Albany Molecular Res Inc | Glycin-transporter-1-hemmer, verfahren zu ihrer herstellung und ihre verwendung |
| KR101464429B1 (ko) | 2012-03-16 | 2014-11-27 | 한국생명공학연구원 | 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용 |
| WO2013137628A1 (ko) * | 2012-03-16 | 2013-09-19 | 한국생명공학연구원 | 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP3587406B1 (de) | 2013-03-13 | 2021-01-27 | Forma Therapeutics, Inc. | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-on-derivate und ähnliche verbindungen als fettsäuresynthase (fasn) inhibitoren zur behandlung von krebs |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN104422738B (zh) * | 2013-08-28 | 2016-12-28 | 北大方正集团有限公司 | 一种分离分析米力农的方法 |
| AU2016263510B2 (en) * | 2015-05-20 | 2020-03-12 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| CN107698606B (zh) * | 2017-08-24 | 2019-12-20 | 迪嘉药业集团有限公司 | 一种他达拉非有关物质f的制备方法 |
| EP3737680A1 (de) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazine als magl-inhibitoren |
| HRP20230388T1 (hr) | 2018-03-22 | 2023-06-23 | F. Hoffmann - La Roche Ag | Inhibitori oksazin monoacilglicerol lipaze (magl) |
| EP3837263B1 (de) | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | Neue heterocyclische verbindungen als monoacylglycerin-lipase-inhibitoren |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| EP3883936B1 (de) | 2018-11-22 | 2023-07-12 | F. Hoffmann-La Roche AG | Neue heterocyclische verbindungen |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
| US11814375B2 (en) | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198449A (en) * | 1990-04-27 | 1993-03-30 | A. H. Robins Company Incorporated | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents |
| DE4326344A1 (de) * | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| EA200200847A1 (ru) * | 2000-02-11 | 2003-02-27 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| IT1319226B1 (it) | 2000-10-19 | 2003-09-26 | Fondmetal Spa | Cerchione con rivestimento decorativo. |
| MXPA03008356A (es) * | 2001-03-13 | 2003-12-11 | Schering Corp | Compuestos del tipo no imidazol como antagonistas de histamina h3. |
| JP2005502623A (ja) * | 2001-07-02 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 置換ピペラジンおよびジアゼパン |
| KR20040099449A (ko) | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| DK1499316T3 (da) | 2002-04-18 | 2008-07-21 | Schering Corp | (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister |
| EP1539742B1 (de) | 2002-06-24 | 2006-11-08 | Schering Corporation | Als histamin-h3-antagonisten geeignete indolderivate |
| AR041198A1 (es) * | 2002-10-11 | 2005-05-04 | Otsuka Pharma Co Ltd | Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen |
| US20040198743A1 (en) * | 2003-01-31 | 2004-10-07 | Schering Corporation | Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists |
| GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| DE602004015269D1 (de) * | 2003-04-23 | 2008-09-04 | Glaxo Group Ltd | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. |
| US20040224952A1 (en) | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
-
2006
- 2006-06-19 AT AT06785168T patent/ATE450525T1/de not_active IP Right Cessation
- 2006-06-19 US US11/455,873 patent/US7408066B2/en not_active Expired - Fee Related
- 2006-06-19 JP JP2008518306A patent/JP2008543940A/ja active Pending
- 2006-06-19 EP EP06785168A patent/EP1896453B1/de active Active
- 2006-06-19 DE DE602006010864T patent/DE602006010864D1/de active Active
- 2006-06-19 MX MX2007016523A patent/MX2007016523A/es active IP Right Grant
- 2006-06-19 CN CNA2006800221722A patent/CN101203510A/zh active Pending
- 2006-06-19 WO PCT/US2006/023937 patent/WO2007002057A1/en not_active Ceased
- 2006-06-19 CA CA002609957A patent/CA2609957A1/en not_active Abandoned
- 2006-06-19 ES ES06785168T patent/ES2337728T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007016523A (es) | 2008-03-06 |
| DE602006010864D1 (de) | 2010-01-14 |
| EP1896453B1 (de) | 2009-12-02 |
| HK1114850A1 (en) | 2008-11-14 |
| US20070010513A1 (en) | 2007-01-11 |
| EP1896453A1 (de) | 2008-03-12 |
| ES2337728T3 (es) | 2010-04-28 |
| JP2008543940A (ja) | 2008-12-04 |
| US7408066B2 (en) | 2008-08-05 |
| WO2007002057A1 (en) | 2007-01-04 |
| CA2609957A1 (en) | 2007-01-04 |
| CN101203510A (zh) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450525T1 (de) | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten | |
| MX2008000115A (es) | Derivados de piperidina utiles como antagonistas de histamina h3. | |
| MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| JP2010538076A5 (de) | ||
| PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
| CY1117946T1 (el) | Ετεροκυκλικοι αναστολεις ασπαραγινυλο πρωτεασης | |
| AR049089A1 (es) | Derivados de adamantil pirrolidin -2- ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR040351A1 (es) | Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| JP2007518682A5 (de) | ||
| PE20080205A1 (es) | DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2 | |
| JP2012510502A5 (de) | ||
| MX2009013335A (es) | Derivados de piperidina/piperazina. | |
| JP2008525417A5 (de) | ||
| ME02766B (de) | Arylmethoxyisoindolinderivate, zusammensetzungen damit und anwendungsverfahren dafür | |
| JP2017511357A5 (de) | ||
| TW200628154A (en) | Organic compounds | |
| PE20081889A1 (es) | Indol carboxamidas como inhibidores de ikk2 | |
| DK1633340T3 (da) | Forbindelser til behandling af stofskifteforstyrrelser | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
| MX2011009700A (es) | Derivado de amida. | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| AR051802A1 (es) | Heterociclos antagonistas de mchr1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |